p450 - publications
Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users.
J Thromb Haemost. 2012 Sep 28;
Authors: Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH, The EU-PACT group
Anticoagulant treatment with phenprocoumon is challenging because of the narrow therapeutic range and the wide inter- and intra-patient variability in dose response. Frequent monitoring of the international normalized ratio (INR) is therefore required. Polymorphisms in two genes, CYP2C9 and VKORC1 explain approximately one third of the variation in dose requirements [1-3]. © 2012 International Society on Thrombosis and Haemostasis.
PMID: 23016521 [PubMed - as supplied by publisher]